SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Boston Scientific Corp. – ‘8-K’ for 4/28/21

On:  Wednesday, 4/28/21, at 6:34am ET   ·   For:  4/28/21   ·   Accession #:  885725-21-12   ·   File #:  1-11083

Previous ‘8-K’:  ‘8-K’ on 3/11/21 for 3/9/21   ·   Next:  ‘8-K’ on 5/11/21 for 5/6/21   ·   Latest:  ‘8-K’ on 5/13/21 for 5/10/21

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/28/21  Boston Scientific Corp.           8-K:2,9     4/28/21   13:644K

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     28K 
 2: EX-99.1     EX-99.1 Q1 2021 Earnings Release                    HTML    112K 
 9: R1          Cover Document                                      HTML     53K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- bsx-20210428_htm                    XML     30K 
10: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.CAL  XBRL Calculations -- bsx-20210428_cal                XML      7K 
 5: EX-101.DEF  XBRL Definitions -- bsx-20210428_def                 XML     41K 
 6: EX-101.LAB  XBRL Labels -- bsx-20210428_lab                      XML     87K 
 7: EX-101.PRE  XBRL Presentations -- bsx-20210428_pre               XML     42K 
 3: EX-101.SCH  XBRL Schema -- bsx-20210428                          XSD     13K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               14±    21K 
13: ZIP         XBRL Zipped Folder -- 0000885725-21-000012-xbrl      Zip     32K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C: 
  bsx-20210428  
 i 0000885725 i false00008857252021-04-282021-04-280000885725us-gaap:CommonStockMember2021-04-282021-04-280000885725bsx:SeniorNotedue2027Member2021-04-282021-04-280000885725bsx:A550MCPSSeriesAMember2021-04-282021-04-28


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_____________________________________________________________________

FORM  i 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________

Date of Report (Date of earliest event reported):  i April 28, 2021

 i BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)

 i Delaware i 1-11083 i 04-2695240
(State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
     i 300 Boston Scientific Way,  i Marlborough,  i Massachusetts                  i 01752-1234
    (Address of Principal Executive Offices)                           (Zip Code)

 i 508  i 683-4000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 i Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
 i Common Stock, $0.01 par value per share i BSX i New York Stock Exchange
 i 0.625% Senior Notes due 2027 i BSX27 i New York Stock Exchange
 i 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share i BSX PR A i New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   



ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On April 28, 2021, Boston Scientific Corporation issued a press release announcing financial results for the first quarter ended March 31, 2021. A copy of the release is furnished with this report as Exhibit 99.1.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.


ITEM 9.01.     FINANCIAL STATEMENTS AND EXHIBITS.

(d)  Exhibits


Exhibit No.        Description

99.1            Press Release issued by Boston Scientific Corporation dated April 28, 2021

104            Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL
            document





SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                        
                                

Date:April 28, 2021BOSTON SCIENTIFIC CORPORATION
By:/s/ Vance R. Brown
Vance R. Brown
Vice President and Chief Corporate Counsel


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:4/28/21None on these Dates
3/31/21
 List all Filings 
Top
Filing Submission 0000885725-21-000012   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Jun. 12, 10:35:50.0pm ET